title: Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
abstract: OBJECTIVE
  The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC). The levels of alanine aminotransferase (ALT) and α-fetoprotein (AFP) as suppressive markers of HCC were also measured.
  
  
  METHODS
  Patients received daclatasvir and asunaprevir (n = 17), simeprevir plus PEG-IFN/RBV (n = 15) and telaprevir plus PEG-IFN/RBV (n = 25). Sustained virological response (SVR) and the mean change in the level of serum ALT, AFP and platelet (PLT) count were compared among the three groups.
  
  
  RESULTS
  No difference in SVR was observed in patients given daclatasvir with asunaprevir (SVR4), telaprevir plus PEG-IFN/RBV or simeprevir plus PEG-IFN/RBV (SVR24). Also, no significant difference was observed in the mean change of serum ALT, AFP or PLT count among the three groups.
  
  
  CONCLUSIONS
  The preventive effect of the IFN-free, all-oral regimen of daclatasvir and asunaprevir was observed with a focus on the occurrence and recurrence of HCC, as was IFN-based treatment with telaprevir or simeprevir plus PEG-IFN/RBV.
authors.affiliation: Division of Molecular Medicine and Medical Genetics, Kobe University Graduate School of Medicine, Kobe, Japan.
authors.forename: Kayo
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Soo Ryang
authors.initials: SR
authors.lastname: Kim
authors.forename: Soo Ki
authors.initials: SK
authors.lastname: Kim
authors.forename: Susumu
authors.initials: S
authors.lastname: Imoto
authors.forename: Madoka
authors.initials: M
authors.lastname: Tohyama
authors.forename: Ke Ih
authors.initials: KI
authors.lastname: Kim
authors.forename: Aya
authors.initials: A
authors.lastname: Ohtani
authors.forename: Takashi
authors.initials: T
authors.lastname: Hatae
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Yano
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
authors.forename: Yoshitake
authors.initials: Y
authors.lastname: Hayashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use*; D002219:Carbamates; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007546:Isoquinolines / Q000627:therapeutic use; D007564:Japan / Q000453:epidemiology; D008113:Liver Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D009367:Neoplasm Staging; D009842:Oligopeptides / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D011379:Prognosis; D011759:Pyrrolidines; D012367:RNA, Viral / Q000235:genetics; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D000069616:Simeprevir / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives; D019562:Viral Load; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007546:Isoquinolines; D009842:Oligopeptides; D011759:Pyrrolidines; D012367:RNA, Viral; D011994:Recombinant Proteins; D013449:Sulfonamides; D000509:alpha-Fetoproteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; D000069616:Simeprevir; C417083:peginterferon alfa-2b; D014633:Valine; C549273:daclatasvir; C571889:asunaprevir